March 04, 2021
Article
Investigators are set to begin testing sulfasalazine and auronofin, which are FDA-approved to treat rheumatoid arthritis, in cancer cell models.
Research over the past decade has shown that PV can be associated with a reduction in survival compared with age- and gender-matched population controls.
The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.
March 03, 2021
There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.
Many rural areas identify with many barriers in their community, such as transportation, technology access, human factors, and the design of the health care model.
Recent data have shown alarmingly low rates of human papillomavirus (HPV) vaccine completion among children between 10 and 13 years of age.
One way of approaching the process of allowing patients to self-report their symptoms is through an electronic patient-reported outcomes (ePRO) system.
March 02, 2021
Although there have been many challenges and concerns during the pandemic, experts said there are also lessons to be learned and implemented once the pandemic is over.
The CDC recommends that patients with cancer and COVID-19 have a conversation with their health care provider or care team to discuss the individual level of risk based on the patient’s current condition, treatment, and the level of transmission within their community.
A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.
